Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + FOLFIRI in Advanced Colorectal Cancer
NCT06855849Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in colorectal cancer (CRC), sponsored by Yonsei University. Planned start May 2025; status: not yet recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06855849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855849.